362 related articles for article (PubMed ID: 26601868)
21. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
22. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
23. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
24. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
26. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
[TBL] [Abstract][Full Text] [Related]
28. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
Ambrosini G; Khanin R; Carvajal RD; Schwartz GK
Mol Cancer Ther; 2014 Aug; 13(8):2073-80. PubMed ID: 24899684
[TBL] [Abstract][Full Text] [Related]
30. Current molecular and clinical insights into uveal melanoma (Review).
Fallico M; Raciti G; Longo A; Reibaldi M; Bonfiglio V; Russo A; Caltabiano R; Gattuso G; Falzone L; Avitabile T
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649778
[TBL] [Abstract][Full Text] [Related]
31. Pathology and genetics of uveal melanoma.
Griewank KG; Murali R
Pathology; 2013 Jan; 45(1):18-27. PubMed ID: 23222249
[TBL] [Abstract][Full Text] [Related]
32. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.
Jager MJ; Dogrusöz M; Woodman SE
Asia Pac J Ophthalmol (Phila); 2017; 6(2):179-185. PubMed ID: 28399339
[TBL] [Abstract][Full Text] [Related]
33. Biology of advanced uveal melanoma and next steps for clinical therapeutics.
Luke JJ; Triozzi PL; McKenna KC; Van Meir EG; Gershenwald JE; Bastian BC; Gutkind JS; Bowcock AM; Streicher HZ; Patel PM; Sato T; Sossman JA; Sznol M; Welch J; Thurin M; Selig S; Flaherty KT; Carvajal RD
Pigment Cell Melanoma Res; 2015 Mar; 28(2):135-47. PubMed ID: 25113308
[TBL] [Abstract][Full Text] [Related]
34. [What else can we do for uveal melanoma].
Li B; Xu XL
Zhonghua Yan Ke Za Zhi; 2009 Apr; 45(4):289-92. PubMed ID: 19575957
[TBL] [Abstract][Full Text] [Related]
35. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
[TBL] [Abstract][Full Text] [Related]
36. A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
Itchins M; Ascierto PA; Menzies AM; Oatley M; Lo S; Douraghi-Zadeh D; Harrington T; Maher R; Grimaldi AM; Guminski A
Melanoma Res; 2017 Jun; 27(3):243-250. PubMed ID: 28230715
[TBL] [Abstract][Full Text] [Related]
37. Recent approaches for the treatment of uveal melanoma: Opportunities and challenges.
Khan SA; Almalki WH; Arora S; Kesharwani P
Crit Rev Oncol Hematol; 2024 Jan; 193():104218. PubMed ID: 38040071
[TBL] [Abstract][Full Text] [Related]
38. Selumetinib-based therapy in uveal melanoma patient-derived xenografts.
Decaudin D; El Botty R; Diallo B; Massonnet G; Fleury J; Naguez A; Raymondie C; Davies E; Smith A; Wilson J; Howes C; Smith PD; Cassoux N; Piperno-Neumann S; Roman-Roman S; Némati F
Oncotarget; 2018 Apr; 9(31):21674-21686. PubMed ID: 29774094
[TBL] [Abstract][Full Text] [Related]
39. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease.
Shildkrot Y; Wilson MW
Curr Opin Ophthalmol; 2009 Nov; 20(6):504-10. PubMed ID: 19644367
[TBL] [Abstract][Full Text] [Related]
40. New immunotherapy approaches as the most effective treatment for uveal melanoma.
Eteghadi A; Ebrahimi M; Keshel SH
Crit Rev Oncol Hematol; 2024 Feb; 194():104260. PubMed ID: 38199429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
